Ipsen has gambled up to $610 million on a new class of bispecific T-cell engagers. The biobuck bet has landed the French drugmaker exclusive global rights to a preclinical Biomunex Pharmaceuticals prospect that engages a subset of cytotoxic T cells known as mucosal-associated invariant T cells (MAITs) with potent cytotoxic capacity that are found in solid tumors. Source: Fierce Biotech 3/12/2024